| US 7,514,069 B2 | ||
| Tumor-targeted optical contrast agents | ||
| Samuel I. Achilefu, St. Louis, Mo. (US); Raghavan Rajagopalan, Solon, Ohio (US); Richard B. Dorshow, St. Louis, Mo. (US); Joseph E. Bugaj, St. Charles, Mo. (US); and Muthunadar P. Periasamy, Chesterfield, Mo. (US) | ||
| Assigned to Mallinckrodt Inc., Hazelwood, Mo. (US) | ||
| Filed on Mar. 05, 2007, as Appl. No. 11/682,032. | ||
| Application 11/682032 is a division of application No. 10/654033, filed on Sep. 03, 2003, granted, now 7,198,778. | ||
| Application 10/654033 is a continuation in part of application No. 09/863971, filed on May 23, 2001, granted, now 6,641,798. | ||
| Application 09/863971 is a continuation in part of application No. 09/484320, filed on Jan. 18, 2000, granted, now 6,180,087. | ||
| Prior Publication US 2008/0008655 A1, Jan. 10, 2008 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61B 10/00 (2006.01); A61B 5/00 (2006.01); A61B 8/00 (2006.01) | ||
| U.S. Cl. 424—9.6 [424/1.11; 424/1.49; 424/1.65; 424/1.69; 424/1.73; 424/9.1; 548/300.1] | 13 Claims |
1. A compound of formula
 W4 and X4 are —NR3;
Y4 is selected from the group consisting of —(CH2)a—CONH-Bm, —CH2—(CH2OCH2)b—CH2—CONH-Bm, —(CH2)a—NHCO-Bm, —CH2—(CH2OCH2)b—CH2—NHCO-Bm, —(CH2)a—N(R3)—(CH2)b—CONH-Bm, (CH2)a—N(R3)—(CH2)c—NHCO-Bm, —(CH2)a—N(R3)—CH2—(CH2OCH2)b—CH2—CONH-Bm, —(CH2)a—N(R3)—CH2—(CH2OCH2)b—CH2—NHCO-Bm, —CH2—(CH2OCH2)b—CH2—N(R3)—(CH2)a—CONH-Bm, —CH2—(CH2OCH2)b—CH2—N(R3)—(CH2)a—NHCO-Bm, —CH2—(CH2OCH2)b—CH2—N(R3)—CH2—(CH2OCH2)d—CONH-Bm, CH2—(CH2OCH2)b—CH2—N(R3)—CH2—(CH2OCH2)d—NHCO-Bm, —(CH2)a—NR3R4, and —CH2(CH2OCH2)b—CH2NR3R4;
Z4 is selected from the group consisting of —(CH2)a—CONH-Dm, —CH2—(CH2OCH2)b—CH2—CONH-Dm, —(CH2)a—NHCO-Dm, —CH2—(CH2OCH2)b—CH2—NHCO-Dm, —(CH2)a—N(R3)—(CH2)b—CONH-Dm, (CH2)a—N(R3)—(CH2)c—NHCO-Dm, —(CH2)a—N(R3)—CH2—(CH2OCH2)b—CH2—CONH-Dm, —(CH2)a—N(R3)—CH2—(CH2—NHCO-Dm, —CH2—(CH2OCH2)b—CH2—N(R3)—(CH2)a—CONH-Dm, —CH2—(CH2OCH2)b—CH2—N(R3)—(CH2)a—NHCO-Dm, —CH2—(CH2OCH2)b—CH2—N(R3)—CH2—(CH2OCH2)d—CONH-Dm, —CH2—(CH2OCH2)b—CH2—N(R3)—CH2—(CH2OCH2)d—NHCO-Dm, —(CH2)a—NR3R4, and —CH2(CH2OCH2)b—CH2NR3R4;
A2 is a single or a double bond;
B2, C2, and D2 are independently selected from the group consisting of —O—, —S—, —Se—, —P—, —CR1R2, —CR1, alkyl, NR3, and —C═O; A2, B2, C2, and D2 together form a 6- to 12-membered carbocyclic ring or a 6- to 12-membered heterocyclic ring optionally containing one or more
oxygen, nitrogen, or sulfur atom;
a4 and b4 are independently from 0 to 5;
R1 to R4 and R45 to R57 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C20 aryl, C1-C10 alkoxyl, C1-C10 polyalkoxyalkyl, C1-C20 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, C1-C10 aminoalkyl, cyano, nitro, halogen, saccharide, peptide, —CH2(CH2OCH2)b—CH2—OH, —(CH2)a—CO2H, —(CH2)a—CONH-Bm, —CH2—(CH2OCH2)b—CH2—CONH-Bm, —(CH2)a—NHCO-Bm, —CH2—(CH2OCH2)b—CH2—NHCO-Bm, —(CH2)a—OH and —CH2—(CH2OCH2)b—CO2H; Bm and Dm are independently selected from the group consisting of a bioactive peptide, a protein, a cell, an antibody,
an antibody fragment, a saccharide, a glycopeptide, a peptidomimetic, a drug, a drug mimic, a hormone, a metal chelating agent,
a radioactive or nonradioactive metal complex, and an echogenic agent;
a and c are independently from 1 to 20; and
b and d are independently from 1 to 100.
|